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Abstract
Background: Urinary sulfate (SO4
22) and thiosulfate (S2O3
22) can potentially bind with calcium and decrease kidney stone
risk. We modeled the effects of these species on the concentration of ionized calcium (iCa) and on supersaturation (SS) of
calcium oxalate (CaOx) and calcium phosphate (CaP), and measured their in vitro effects on iCa and the upper limit of
stability (ULM) of these salts.
Methods: Urine data from 4 different types of stone patients were obtained from the Mayo Nephrology Clinic (Model 1). A
second data set was obtained from healthy controls and hypercalciuric stone formers in the literature who had been treated
with sodium thiosulfate (STS) (Model 2). The Joint Expert Speciation System (JESS) was used to calculate iCa and SS. In
Model 1, these parameters were calculated as a function of sulfate and thiosulfate concentrations. In Model 2, data from
pre- and post STS urines were analyzed. ULM and iCa were determined in human urine as a function of sulfate and
thiosulfate concentrations.
Results: Calculated iCa and SS values for all calcium salts decreased with increasing sulfate concentration. Thiosulfate had
no effect on these parameters. In Model 2, calculated iCa and CaOx SS increased after STS treatment, but CaP SS decreased,
perhaps due to a decrease in pH after STS treatment. In confirmatory in vitro experiments supplemental sulfate, but not
thiosulfate, significantly increased the calcium needed to achieve the ULM of CaP and tended to increase the oxalate
needed to reach the ULM of CaOx. Sulfate also significantly decreased iCa in human urine, while thiosulfate had no effect.
Conclusion: Increasing urinary sulfate could theoretically reduce CaOx and CaP stone risk. Although STS may reduce CaP
stone risk by decreasing urinary pH, it might also paradoxically increase iCa and CaOx SS. As such, STS may not be a viable
treatment option for stone disease.
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Introduction
The majority of kidney stones are composed of calcium salts,
mainly calcium oxalate (CaOx) and calcium phosphate (CaP) [1].
The risk of stone formation increases as the urine reaches
supersaturation (SS) for these and other stone forming crystals
and surpasses the threshold of spontaneous crystallization known
as the upper level of metastability (ULM) [2]. SS reflects the
concentration of a dissolved salt relative to the solubility of that salt
in urine at body temperature [2]. Human urine is frequently
supersaturated for stone-forming crystals, especially calcium
oxalate [2]. Urinary SS predicts stone type as well as risk of
recurrence [3]. It has been suggested that an individual’s
susceptibility to stone formation is reflected by the difference
between their ambient urine SS and the ULM threshold,
particularly for CaP, since the greater the difference between the
SS and ULM, the less likely a given crystal should spontaneously
nucleate [2,4].
Endogenous and exogenous sulfate (SO4
22) and thiosulphate
(S2O3
22) have both been reported as affecting urinary lithogenic
risk factors physiologically or physico-chemically. Sulfate is
primarily produced by sulfur amino acid oxidation, which is
largely eliminated by the kidney in the form of a titratable acid [5].
In general, urinary SO4
22 reflects intake of dietary proteins
containing cystine and methionine [6], although 2 members of the
SLC13 family of sodium-coupled sulfate/carboxylate transporters
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are widely distributed in renal and gastrointestinal epithelia [7]. In
particular NaS1 and NaS2 are thought largely responsible for
renal sulfate reabsorption while NaC1 and NaC2 are important
for citrate reabsorption, and all are under physiological and
hormonal regulatory influences [7]. In addition, oxalate-sulfate
exchange has recently been ascribed to the SLC26A2 transporter
found in both intestine and kidney brush border [8]. Thus, local
sulfate concentrations could influence gut absorption and/or renal
secretion of anions important in stone disease such as oxalate and
citrate. Independent of these considerations, (SO4
22) is a divalent
anion and has the capacity to bind with ionized calcium (iCa) in
urine, thereby decreasing its availability for complexation with free
oxalate and phosphate and concomitantly decreasing CaOx and
CaP SS.
Thiosulfate (S2O3
22) is also a divalent anion, which therefore
has the same potential capacity as sulfate for binding with Ca.
Indeed, it has been proposed as a treatment for calcium
nephrolithiasis following a clinical study in which urinary iCa
levels and formation rates of recurrent kidney stones were
significantly reduced after administration of sodium thiosulphate
(STS) to a group of idiopathic calcium stone formers [9]. The
authors hypothesized that formation of a calcium thiosulphate
complex as a possible mechanism of the apparent beneficial effect.
A subsequent study in genetic hypercalciuric stone-forming rats
confirmed that STS administration reduced spontaneous stone
formation but iCa did not change appreciably, and the authors
expressed doubt about the formation of a calcium thiosulphate
complex [10]. Recently, STS was administered to healthy controls
and idiopathic hypercalciuric stone-forming patients in a pilot
study [11]. Although iCa concentrations were not measured,
changes in other urinary parameters did not support the
hypothesis that STS could prevent stone formation.
Thus the respective roles, if any, of urinary sulfate and
thiosulphate in idiopathic stone disease pathogenesis or therapy
remain unresolved. Therefore, in the current study modeling
calculations were performed to predict the effects of sulfate and
thiosulfate on urinary iCa concentration and on CaOx and CaP
SS, and to test these calculations by determining iCa and ULM in
urine samples augmented with each.
Methods
Representative urine values
Mayo Clinic Stone Disease Data Base (Urine Model
1). The Mayo Clinic Institutional Review Board approved this
study. In order to obtain representative ‘‘real world’’ urine values
for in silico studies, patients were identified from the Mayo
Nephrology Clinic with a history of stone disease in each of the
following groups (i) patients with a history of symptomatic stone
passage containing a majority CaOx, without a history of enteric
hyperoxaluria (n = 15); (ii) patients with a history of symptomatic
stone passage containing a majority apatite or brushite (n = 13); (iii)
patients with a history of cystinuria as confirmed by stone analysis
or increased urinary cystine excretion (n= 10); (iv) patients with a
Figure 1. JESS-calculated concentration of calcium species as a function of [SO4
22] concentrations. Average urine values from a group
of calcium oxalate stone formers were used (Table 1), and sulfate varied from baseline (100%) to as low as 10% or as high as 500% of that.
doi:10.1371/journal.pone.0103602.g001
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history of symptomatic stone passage containing a majority uric
acid (n = 11). These 24-hr urine samples were collected using
toluene as a preservative as per the laboratory practice. The first
complete urine panel in the medical record was abstracted for
further analysis. The relatively high mean pH values in the uric
acid and cystine stone formers indicate that these patients were
likely to have been receiving some kind of therapy, but this was not
regarded as a confounding factor in the modelling exercises
described in this paper.
STS Pilot Study: Normal Controls and Hypercalciuric
Stone Formers (Urine Model 2). Urine data obtained before
and after STS ingestion by a group of healthy controls and
hypercalciuric stone formers [11] constituted our second urine
model. The control group consisted of 5 healthcare volunteers (3
males, 2 females, mean age 33 years) with no history of urolithiasis.
Participants in the patient group (4 males, 1 female, mean age 66
years) were documented stone formers with a history of
hypercalciuria. Mean urinary data for all of the participants in
each of the respective groups, as reported in the original study
[11], were used in our calculations. Twenty four hour urinary Mg,
Cl, and S2O3
22 excretions and urinary volumes, which were not
reported in the original paper, were kindly provided by J. Asplin
(Litholink Corporation, Chicago). Baseline urinary S2O3
22
excretions were not measured, but after STS ingestion the average
excretions were 0.61 and 0.59 mM/d for controls and patients,
respectively. This converts to concentrations of 2.8461024 M and
2.8261024 M, based on the mean 24 h urinary volumes of 2.15
liters and 2.09 liters respectively. However, for our modeling we
used a slightly higher concentration of 5.061024 M for S2O3
22 in
the respective groups for the post STS urine composition, to cover
the top of the range of values reported in other studies after STS
ingestion [12,13]. For the baseline concentration of S2O3
22, we
used a value of 1.061025 M in accordance with the concentration
previously reported for healthy controls [13].
Calculation of speciation concentrations and SS
values. The speciation program JESS (Joint Expert Speciation
System, Version 6.5) [14,15] was used to calculate the concentra-
tion of iCa and various other urinary ionic species as well as SS of
calcium oxalate and calcium phosphate salts in both models. JESS
has the same limitations as those of other thermodynamic
speciation programs, namely that it does not take into account
kinetic phenomena and its accuracy is limited to that of its
database of thermodynamic constants. However, the latter is
extremely comprehensive in JESS as it includes published
constants from multiple studies. Unlike other programs, it
interrogates the database for each particular calculation that it is
asked to perform and highlights potential anomalies for the user
who is then required to select constants which are appropriate for
that particular calculation. Herein lies the ‘‘Expert’’ aspect of the
program. It can readily be appreciated that use of JESS is not
routine; as such this may be regarded as one of its limitations.
Figure 2. JESS-calculated concentration of calcium species as a function of [S2O3
22] concentrations. Average urine values from a group
of calcium oxalate stone formers were used (Table 1), and sulfate varied from 1025 M to 1023 M.
doi:10.1371/journal.pone.0103602.g002
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In Model 1, the calculations were performed at the ambient
urine sulfate concentration for each of the four classes of stone-
formers, and at 10%, 200% and 500% of this value. Thiosulfate
was then included in this model at low and high concentrations to
examine its effect on the concentration of iCa and SS values. The
low concentration of S2O3
22 was set at 1.061025 M [13] while
the high concentration was set at 1006this level (1.061023 M) for
modeling purposes. Importantly, this concentration is significantly
in excess of levels reported after administration of STS in a pilot
clinical trial [11].
In Model 2, calculation of SS values and concentrations of
ionized species were performed in the baseline and post STS urine
values of normal controls and hypercalciuric stone formers. In
order to ascertain the effect of pH alone, the calculations were
repeated using the baseline compositions, but with the pH
changed to that observed in the post STS urines. Similarly, in
order to assess the effect of S2O3
22 alone, the calculations were
repeated, again using the baseline compositions and pH, but this
time with the S2O3
22 concentration changed to that observed
after STS ingestion.
Upper limits of metastability. ULMCaOx and ULMCaP
were measured in human urine using a modification of the method
of Asplin and colleagues [10]. Waste urine samples were obtained
from stone formers and controls in whom urinary measurements
for SS calculations, including sulfate, were already available.
Urines were provided by the Mayo Clinic Renal Laboratory,
maintained at 4uC, and studied within 24 hours of receipt.
Validation data from this laboratory have previously confirmed
that all analytes relevant for supersaturation calculations are stable
for 7 days at this temperature. Urine pH was adjusted (using HCl
or NaOH) to 5.7 (for CaOx ULM) or 6.4 (for CaP ULM). The
sample was centrifuged at 3,000 rpm for 10 min, and 2 ml aliquot
of the sample was transferred into a cuvette of a Cary Bio 50 UV-
Visible spectrophotometer (Varian, now Agilent Technologies
Inc., Santa Clara, CA). The analysis wavelength was set to
620 nm, and the threshold absorbance was set to 0.07. The
cuvette was stirred at 37uC using a temperature-controlled peltier
(Quantum Northwest, Liberty Lake, WA). Every 2.5 min, 5 ml of
CaCl2 for CaP ULM or 5 ml oxalic acid solution for CaOx ULM
was added to the cuvette. When the OD reading reached or
exceeded the absorbance threshold, the assay was discontinued.
For sulfate studies, the urine sulfate was augmented to 2 and 5
times baseline levels using a stock sodium sulfate solution. For
S2O3
22 studies, urines were supplemented to 0.25 mM and
0.5 mM sodium thiosulfate in order to roughly cover the range
seen in patients after STS ingestion [9,11,13]. The final
concentration, either calcium or oxalate, required to reach or
exceed the absorbance threshold was calculated in order to assess
the ULM for CaP and CaOx, respectively using EQUIL2 rather
than JESS, since previous publications on ULM used EQUIL2
[2,4,10]. The pH was maintained at 5.7 (CaOx) or 6.4 (CaP) for all
ULM measurements. Urine samples were not re-refrigerated
between measurements at baseline and after supplementation,
thereby ensuring that any precipitation effects would be common
to both sets of experiments.
iCa determination
A METTLER Toledo PerfectION combination calcium
electrode was used to measure iCa at a pH of 5.7 and 6.4 for
the baseline and after the SO4
22 or S2O3
22 concentration was
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Results
Theoretical Calculations
Urine Model 1. Average baseline urine concentrations for
the 4 groups of stone formers are given in Table 1. JESS-
calculated urinary SS and iCa values are given in Table 2. The
concentration of all Ca species as a function of SO4
22
concentration is shown for the CaOx group in Figure 1. Identical
trends were observed in all of the other patient groups (not shown
here). SS for all Ca salts in all patient groups decreased as the
concentration of SO4
22 increased (Table 2). It was not feasible to
perform statistical comparisons of the parameters at the different
concentrations of SO4
2– because the model concentrations (10%,
200%, and 500%) are theoretical; they were not determined
experimentally. As such, they do not have associated experimental
errors.
The decreases in SS for all Ca salts can be accounted for by
decreases in the concentration of iCa arising from complexation
with SO4
22 to form CaSO4 (Figure 1). It is noted that the
concentrations of all species decreased except those for CaSO4 and
CaCitPO4. While the increase in the concentration of the former
species is obviously due to the increase in the concentration of
SO4
22, the increase in the concentration of the latter species can
be accounted for by an increase in the concentration of [Cit]32
(not shown here) caused by the decrease in the concentration of




22 at low and high concentrations in the
baseline model (corresponding to 100% SO4
22) had no effect on
the SS value of any salt or on the concentration of iCa in any of
the patient groups (Table 2). The stable concentration of iCa and
of all other Ca species as a function of S2O3
22 concentrations is
demonstrated in Figure 2 for the CaOx patient group. Identical
trends were observed in all of the other patient groups (not shown
here).
Urine Model 2. Supersaturation values for various Ca salts,
and concentrations of various ionized species at baseline and after
administration of STS are given in the 1st and 2nd rows in
Table 3 for healthy controls and in Table 4 for hypercalciuric
stone formers. Data corresponding to other urine scenarios,
discussed below, are given in the 3rd and 4th rows in both tables.
Table 2. JESS-calculated SS values and concentration of ionized Ca2+.
COM Bru OCP tCaP HAP Ca2+
CaOx Group
10% SO4 3.45 1.22 348.6 12.34 3.02E+8 8.44E-4
100% SO4 3.15 1.13 274.8 11.36 1.89E+8 7.98E-4
200% SO4 2.87 1.04 219.6 7.79 1.23E+8 7.55E-4
500% SO4 2.25 0.86 130.8 4.66 4.40E+7 6.53E-4
1025 M S2O3 3.15 1.13 274.8 11.36 1.89E+8 7.98E24
1023 M S2O3 3.15 1.13 274.8 11.36 1.80E+5 7.98E24
CaP Group
10% SO4 3.37 1.65 3073 101.9 3.31E+10 7.32E-4
100% SO4 3.22 1.57 2789 94.4 2.96E+10 7.13E-4
200% SO4 3.08 1.50 2512 87.0 2.60E+10 6.93E-4
500% SO4 2.70 1.32 2166 68.8 1.78E+10 6.40E-4
1025 M S2O3 3.22 1.57 2789 94.4 2.96E+10 7.14E24
1023 M S2O3 3.22 1.58 2789 94.4 2.96E+10 7.14E24
UA Group
10% SO4 5.03 1.20 97.9 3.22 1.70E+7 9.10E-4
100% SO4 4.51 1.09 75.6 2.63 1.23E+7 8.43E-4
200% SO4 4.03 0.98 57.9 2.13 8.85E+6 7.82E-4
500% SO4 3.02 0.76 28.3 0.36 3.56E+6 6.48E-4
1025 M S2O3 4.51 1.09 75.6 2.63 1.23E+7 8.42E24
1023 M S2O3 4.50 1.09 75.6 2.63 1.23E+7 8.42E24
Cys Group
10% SO4 1.20 0.91 293.9 13.0 2.67E+8 4.41E-4
100% SO4 1.15 0.87 263.0 11.9 2.29E+8 4.28E-4
200% SO4 1.10 0.83 238.4 10.7 1.96E+8 4.15E-4
500% SO4 0.90 0.75 179.2 8.1 1.31E+8 3.81E-4
1025 M S2O3 1.15 0.87 263.0 11.9 2.29E+8 4.29E24
1023 M S2O3 1.15 0.87 263.0 11.9 2.29E+8 4.28E24
Bru: brushite; CaOx: calcium oxalate; CaP: calcium phosphate; COM: calcium oxalate monohydrate; Cys: cystine; HAP: hydroxyapatite; OCP: octacalcium phosphate; tCaP:
tri-calcium phosphate; UA: uric acid.
Results are presented as a function of [SO4
22] and [S2O3
22] concentrations separately for each of the 4 patient groups in Table 1.
doi:10.1371/journal.pone.0103602.t002
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Calculated COM SS increased after STS ingestion in both
stone formers and controls, while SS for all the CaP salts decreased
(Tables 3 and 4). The same trends are apparent in the CaOx and
BR SS results reported by Okonkwo and colleagues [11]. These
authors did not report SS values for other CaP salts, and used
EQUIL2 to calculate SS. Thus results from the two studies are
complimentary and consistent. Our results also show that the
concentrations [Ca2+] in healthy controls and in stone formers
increased, while those of [Ox22] and [HPO4
22] decreased in post-
STS urines (Tables 3 and 4).
Since our calculations using Model 1 demonstrated that S2O3
22
alone has no effect on iCa or SS of Ca salts, we concluded that the
changes in SS, which were observed in the urines reported by
Okonkwo et al [11] for normal controls and hypercalciuric stone
formers after ingestion of STS (Model 2, Tables 3 and 4), must
have been due to some factor other than complexation between
Ca2+ and S2O3
22. A likely candidate is the statistically significant
decrease in pH which occurred in both groups after ingestion of
STS [11]. In order to test the hypothesis that a change in pH is the
driving force behind the predicted changes in the concentration of
Ca2+ and SS of all of the salts, we performed calculations using the
baseline model in each group, but changing the pH to that which
was measured after STS ingestion. Thus pH was changed from
6.67 to 6.08 and from 6.09 to 5.76 in controls and patients
respectively. This shift in pH led to an increase in the [Ca2+] and a
decrease in [HPO4
22] concentration (3rd row in Tables 3 and
4). The concentration of [Ox 22] changed negligibly. We then
performed another set of calculations, again using the baseline
model, but we increased the concentration of S2O3
22 to that
which was measured after treatment with STS. With the pH held
constant, the concentration of S2O3
22 was increased from
1.061025 M to 2.8461024 M in healthy controls and from
1.061025 M to 2.861024 M in stone formers. No changes
occurred in the SS values of any of the salts or in the
concentrations of any of the ionized species (4th row in Tables 3
and 4), as had been predicted by our modeling calculations
described earlier in this paper. Hence, our model confirms that the
changes in SS values of all salts following ingestion of STS
(Tables 3 and 4) are indeed due to decreases in pH in both
groups, rather than to increases in the concentration of S2O3
22
per se.
The increase in the concentration of iCa calculated in both
groups following STS ingestion can be accounted for by decreases
in the concentrations of several Ca species, particularly that of
Ca2H2(PO4)2, which releases Ca
2+ into the urine milieu, as shown
in Figure 3 for hypercalciuric stone formers. It has been
demonstrated elsewhere that for any given urine, the concentra-
tion of this species (and others) increases as pH increases [16].
Since the concentration of Ca2+ increased after STS ingestion,
the decreases in brushite (Bru) SS, octacalcium phosphate (OCP)
SS, tri-calcium phosphate (tCaP) SS, and hydroxyapatite (HAP)
SS must be accounted for by a larger fractional decrease in the
concentration of [HPO4
22]. This indeed occurs (Tables 3 and 4),
and arises because at the lower pH following STS ingestion,
[HPO4
22] becomes protonated, thereby causing a decrease in its
own concentration and an increase in the concentration of
[H2PO4
21]. The concentration of [PO4
32] itself is negligible at
lower pH values.
The SS of uric acid (UA) increased in both groups after
ingestion of STS (Tables 3 and 4). Okonkwo et al found this
increase to be statistically significant [11]. As with the other effects
described in the preceding paragraphs, the increase in UA SS is
attributed to the decrease in pH. When pH falls the concentration
of H+ increases, thereby shifting the equilibrium towards a higher
Figure 3. JESS-calculated concentration of calcium species as a function of thiosulfate (STS) concentration and pH. Average urine
values from a group of idiopathic hypercalciurics were used before and after STS ingestion [11].
doi:10.1371/journal.pone.0103602.g003
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concentration of undissociated UA. This culminates in an increase
in its SS level.
Upper limits of metastability and iCa concentrations
Figure 4 shows the amount of oxalate or calcium added to
achieve ULM for CaOx and CaP respectively, as the sulfate
concentration was increased to 2 or 5 times that of the baseline.
Only 2 incremental increases were tested since there was no
practical method to decrease urinary sulfate in vitro. The amount
of oxalate or calcium needed to achieve the CaOx and CaP ULM
tended to increase when the sulfate concentration was raised to 5
times the baseline (22%, p= 0.07 and 16%, p= 0.004 for CaOx
and CaP respectively). The effect of exogenous sulfate on iCa is
shown in Figure 5 when pH was held constant at 5.7. All 13
samples showed a decrease in iCa concentration with the average
iCa concentration dropping 25% from 1.2161024 to
8.8761025 mol/l (p,0.001). Similar results were observed at
pH 6.4. Conversely, exogenous S2O3
22 did not change the
amount of calcium or oxalate needed to achieve ULM or alter iCa
in the 11 urine samples studied (Figure 6). Addition of S2O3
22
also did not alter iCa at pH 5.7 (Figure 7) or pH 6.4 (not shown).
Discussion
Our theoretical modeling demonstrated that SO4
22 has a
modest effect reducing the concentration of iCa and, concomi-
tantly, reducing urinary SS of Ca salts. Importantly, our in vitro
measurements confirmed the theoretical prediction of a reduction
in iCa and demonstrated that SO4
22 raises the ULM for CaOx
and CaP (albeit that the increase in ULM for CaOx did not quite
reach statistical significance). As such, its use as a therapeutic agent
in the management of Ca stone formation is worth debating.
An obvious question is whether the urinary excretion of sulfate
differs between healthy controls and stone forming patients.
However, data on urinary sulfate excretion in stone formers as a
group are sparse. One study suggested stone formers had a higher
fractional excretion of sulfate compared to controls [17].
Unfortunately, total sulfate excretion was not reported and diet
was not controlled in this study. A second study of 30 matched
stone formers and controls did not find a difference in total
excretion [18]. In addition, a twin study suggested that urinary
sulfate levels are determined largely by environment, rather than
genetics [19].
Based on the results of our theoretical modeling and in vitro
experimentation, increased urinary sulfate concentrations could
reduce calcium crystal formation. However, it is not obvious how
this can be effectively achieved among stone forming patients.
Short term sulfate loading, whether via sulfate infusion or sulfate
amino acid oxidation, is associated with enhanced urinary calcium
excretion [20]. Indeed, the latter is highly correlated with urinary
sulfate excretion, more so than with urea or sodium excretion,
perhaps due to the variable methionine/cysteine-cystine content of
dietary proteins [21]. In longer term chronic protein loading, the
hypercalciuria may resolve, perhaps due to renal adaptive effects
[22]. Among stone formers lower bone mineral density appears to
correlate with higher urine calcium and ammonium excretion, the
later presumably reflecting a greater acid load [23]. However,
bone mineral density does not appear to correlate with urinary
sulfate excretion. Therefore, the precise relationship between
protein intake, urine sulfate, urine calcium, bone health, and
kidney stone disease remains to be established.
Ammonium sulfate has been used in a small number of patients
with CaP stones with reported decreases in urinary pH, CaP SS
and stone rates, without changes in urinary calcium [24]. L-
methionine has been used in small numbers of similar patients
with CaP stones and possible infection [25]. Although much more
research is needed, small case series such as these suggest that
among CaP stone formers, methods to raise urinary sulfate and
decrease pH may have some merit.
Figure 4. Final oxalate or calcium concentration for achieving
the ULM for CaOx and CaP as a function of sulfate concentra-
tion. Urinary oxalate or calcium is expressed normalized relative to the
baseline concentration in that urine sample. At 56 sulfate, 22% more
oxalate (P = 0.07) and 16% more calcium (P = 0.004) was needed to
reach ULM. Urine samples from 10 stone formers and 3 controls were
studied. *P,0.05.
doi:10.1371/journal.pone.0103602.g004
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Conversely, our theoretical modeling and in vitro experimen-
tation also demonstrated that STS per se has no effect on urinary
iCa or on SS of Ca salts. However, our calculations showed that
the decrease in urinary pH associated with STS ingestion
Figure 5. Change in concentration of urinary iCa as a function of sulfate level. Each thin line represents a different samples and the thicker
line represents the average value. The pH was held constant at 5.7. Urine samples from 10 stone formers and 3 controls were studied. Overall urine
calcium fell 25615%, *P,0.001 versus baseline.
doi:10.1371/journal.pone.0103602.g005
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favorably decreases SS of CaP salts, albeit that it is accompanied
by an unfavorable increase in SS CaOx. Its use as a therapeutic
agent in the treatment of CaP stones is therefore worth
considering.
Recently STS was used in a genetic hypercalciuric CaP stone-
forming rat model [10]. Stone formation dramatically decreased.
Total urine calcium increased and urine pH fell. Ionized Ca was
not directly measured in urine, but measurements in buffered
solutions suggested that STS in concentrations up to 4 mmol/l
would not change urinary iCa sufficiently to explain the beneficial
effects in terms of a reduction in stone formation. The authors
concluded that other mechanisms must be in play. Our data
supports this assertion. For example, as pointed out by the authors
themselves [10], since oxidative stress is believed to be a causative
factor in kidney stone formation [26], the fact that STS is a
powerful reducing agent might be important. However, we suspect
that a more likely explanation for the reported decrease in CaP
stone formation could be the fall in pH, with concomitant
decreases in the SS of all CaP salts, as predicted by our
calculations in the present study.
The potential use of STS for stone prevention was reported in
1985 [9]. In the latter study patients were given 20 mmol/day
STS, which increased urine levels of S2O3
22 from about 0.5 to
4 mmol/day, and decreased urinary iCa from about 3.5 to
2 mmol/day [9]. In this non-controlled trial, stone recurrence
rates fell from 0.98 to 0.11/year. This dose was well tolerated, and
is similar to the amount used orally as secondary prevention of
calciphylaxis in hemodialysis patients [27,28] and in a few patients
with nephrocalcinosis attributed to distal renal tubular acidosis
[29,30]. However, based on the theoretical and experimental
findings of the present study, we find it difficult to understand how
iCa could have decreased. Nor do we agree with the assertion of
the authors that their observations could be attributed to the
formation of a CaS2O3 complex, since we have shown in our
calculations that at concentrations of S2O3
22 approximating those
which they observed in their trial, there is no effect whatsoever on
SS of CaOx and CaP salts (Model 1, Table 2). We are led to
conclude that the decrease in stone recurrence rates which were
observed might have occurred because of a decrease in urinary
pH, which has been reported as being associated with STS
administration [11]. Our results have shown that such a decrease
in pH would lower SS of all CaP salts, possibly culminating in
lower recurrence rates for this type of stone. Unfortunately, the
authors of the earlier study did not report pH values, even though
they stated that these were measured, nor did they indicate what
type of hypercalciuric stone formers constituted their patient group
[9]. We are therefore unable to test our hypothesis using the data
provided in that study.
In a recent short term pilot study involving STS administration
to 5 stone formers and 5 controls, investigators found decreases in
urine pH and citrate and increases in urine sulfate, calcium, and
ammonium [11]. The increase in urine ammonium is consistent
with an acid load. Unfortunately, urinary iCa was not measured.
As discussed earlier, an isolated increase in urinary sulfate is likely
to modestly reduce SS of Ca salts. However, in this trial calculated
CaOx SS did not fall, likely due to concurrent changes in other
urine chemistries such as calcium and citrate [11]. Although the
dose of STS was 20/mmol day, replicating the Yatzidis protocol
[9], an average of only 0.60 mmols/d (range 0.33 to 1.22 mmols/
d) was measured in the urine. Thus the amount of an oral STS
load that makes it into final urine may be less than the earlier study
suggested. The authors concluded that their urine chemistry
results did not support the notion of STS preventing stones in rats
or humans, as reported in earlier studies mentioned above [11].
The predicted ability of SO4
22 on the one hand, and the failure
of S2O3
22 on the other hand, to exert an effect on the urinary
concentration of ionized Ca2+ and on concomitant supersaturation
values for urinary Ca salts demonstrated by our speciation
modeling can be explained in terms of fundamental physicochem-
ical principles. Firstly, since SO4
22 and S2O3
22 have to compete
with urinary citrate to have an impact on the concentration of
ionized [Ca2+], the respective thermodynamic binding constants
(K) for the formation of [CaCit21], [CaSO4] and [CaS2O3] need
to be considered. Log K values for these complexes are
respectively 3.31, 1.50 and 1.05 [15]. Comparison of these values
Figure 6. Final oxalate or calcium concentration for achieving
the ULM for CaOx and CaP as a function of thiosulfate
concentration. Urinary oxalate or calcium is expressed normalized
relative to the baseline concentration in that urine sample. At 0.5 mM
thiosulfate, 38% more oxalate (P = 0.23) and 4% less calcium (P= 0.27)
was needed to reach ULM. Urine samples from 9 stone formers and 2
controls were studied.
doi:10.1371/journal.pone.0103602.g006
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shows that the [CaCit21] complex is 636more stable than that of
the corresponding [CaSO4] complex and 1826more stable than
that of the corresponding [CaS2O3] complex. Secondly, since the
physiological concentration of SO4
22 is 1.3461022 M [31] and
that of S2O3
22 is 1.061025 M [13] while that of citrate is
1.9061023 M [31], it is apparent that SO4
22 would be able to
compete with citrate in the formation of [CaSO4] only if its
concentration is raised to a level which is about one order of
magnitude greater than its normal value while that of S2O3
22
would have to be raised to several orders of magnitude greater
than that of its normal value. Indeed, competition between citrate
and SO4
22 is demonstrated in the formation of [CaCitPO4] which
has been explained above in the Results section for urine model 1.
Since achievement of these concentrations for S2O3
22 in urine is
not feasible, it is extremely unlikely, if not impossible, for it to
influence SS of Ca salts. This is clearly demonstrated in Figure 2
which shows the ineffectiveness of S2O3
22 to exert an effect on any
of the Ca species even when its concentration is significantly
Figure 7. Change in concentration of urinary iCa as a function of thiosulfate level. Each thin line represents a different samples and the
thicker line represents the average value. The pH was held constant at 5.7. Overall, iCa did not fall (9868% of baseline; P = 0.41). Urine samples from 8
stone formers and 3 controls were studied.
doi:10.1371/journal.pone.0103602.g007
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greater than that which has been reported after STS administra-
tion. On the other hand, achieving elevated SO4
22 concentrations
is less formidable.
In conclusion, we suggest that increasing urinary sulfate
concentrations may have beneficial effects for reducing SS of
CaOx and CaP salts and raising their upper limits of stability,
thereby reducing their risk of stone formation. Protocols for
achieving the modest increases in urinary SO4
22 required for such
effects are worth exploring. However, while administration of STS
might achieve favorable decreases in SS of CaP salts by virtue of its
ability to reduce urinary pH, the concentration required to achieve
such an effect is not clinically feasible. Additionally, the
concomitant increase in SS CaOx as well as the increased risk
of uric acid stones at the lower pH, greatly reduces the appeal of
the potential use of STS in this context. Finally, a potential
complication of the acid load induced by STS is bone loss. As
such, we believe that STS administration may not be a viable
treatment for Ca stone disease.
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